Exhibit 99.1 atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates • First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H'24; Phase 2 study in TRD patients anticipated to initiate around YE'24 • Beckley Psytech's Phase 2a study of BPL-003 in TRD patients showed rapid and durable antidepressant ef ects; Phase 2b topline data expected in 2H'24 • Compass Pathways' Phase 2 study of COMP360 in PTSD patients demonstrated durable improvement in symptoms; Phas ...